434 related articles for article (PubMed ID: 28128193)
41. Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.
Kim Y; Shiba-Ishii A; Nakagawa T; Husni RE; Sakashita S; Takeuchi T; Noguchi M
Pathol Int; 2017 Jun; 67(6):292-301. PubMed ID: 28544031
[TBL] [Abstract][Full Text] [Related]
42. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
43. ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples.
Kalogeraki A; Karvela-Kalogeraki I; Tamiolakis D; Petraki P; Saridaki Z; Tzardi M
Rev Port Pneumol; 2014; 20(4):200-7. PubMed ID: 24508180
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.
Hofman P; Ilie M; Hofman V; Roux S; Valent A; Bernheim A; Alifano M; Leroy-Ladurie F; Vaylet F; Rouquette I; Validire P; Beau-Faller M; Lacroix L; Soria JC; Fouret P
Ann Oncol; 2012 Jul; 23(7):1738-43. PubMed ID: 22100693
[TBL] [Abstract][Full Text] [Related]
45. The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas.
Shanzhi W; Yiping H; Ling H; Jianming Z; Qiang L
PLoS One; 2014; 9(4):e95479. PubMed ID: 24743427
[TBL] [Abstract][Full Text] [Related]
46. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
Shi SB; Wang M; Tian J; Li R; Chang CX; Qi JL
Transl Res; 2016 Apr; 170():1-7. PubMed ID: 26687391
[TBL] [Abstract][Full Text] [Related]
48. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
49. Thyroid transcription factor 1 and napsin a double staining in lung adenocarcinoma in pleural fluid.
Liu L; Cohen C; Siddiqui MT
Acta Cytol; 2012; 56(4):425-30. PubMed ID: 22846220
[TBL] [Abstract][Full Text] [Related]
50. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
51. Comparison of monoclonal napsin A, polyclonal napsin A, and TTF-1 for determining lung origin in metastatic adenocarcinomas.
Mukhopadhyay S; Katzenstein AL
Am J Clin Pathol; 2012 Nov; 138(5):703-11. PubMed ID: 23086771
[TBL] [Abstract][Full Text] [Related]
52. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
53. Applications and limitations of immunohistochemical expression of "Napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs.
Kadivar M; Boozari B
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):191-5. PubMed ID: 22914608
[TBL] [Abstract][Full Text] [Related]
54. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.
Toki MI; Carvajal-Hausdorf DE; Altan M; McLaughlin J; Henick B; Schalper KA; Syrigos KN; Rimm DL
J Thorac Oncol; 2016 Nov; 11(11):1901-1911. PubMed ID: 27449805
[TBL] [Abstract][Full Text] [Related]
55. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
Oktay E; Oflazoglu U; Varol Y; Tanriverdi O; Mermur N; Arda HU; Demir L; Keskin O; Ahmadli T; Somali I; Oztop I; Meydan N
J Cancer Res Ther; 2020; 16(4):737-744. PubMed ID: 32930112
[TBL] [Abstract][Full Text] [Related]
56. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
57. Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions.
Dejmek A; Naucler P; Smedjeback A; Kato H; Maeda M; Yashima K; Maeda J; Hirano T
Diagn Cytopathol; 2007 Aug; 35(8):493-7. PubMed ID: 17636482
[TBL] [Abstract][Full Text] [Related]
58. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
59. [Association between the ALK Gene Status and the Efficacy of First-line
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
[TBL] [Abstract][Full Text] [Related]
60. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
